These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 35175662)
41. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Gable RS Addiction; 2007 Jan; 102(1):24-34. PubMed ID: 17207120 [TBL] [Abstract][Full Text] [Related]
42. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context. Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972 [TBL] [Abstract][Full Text] [Related]
43. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca. Yritia M; Riba J; Ortuño J; Ramirez A; Castillo A; Alfaro Y; de la Torre R; Barbanoj MJ J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 779(2):271-81. PubMed ID: 12361741 [TBL] [Abstract][Full Text] [Related]
44. Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil. Souza RCZ; Zandonadi FS; Freitas DP; Tófoli LFF; Sussulini A J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Aug; 1124():197-203. PubMed ID: 31220748 [TBL] [Abstract][Full Text] [Related]
45. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Riba J; Anderer P; Jané F; Saletu B; Barbanoj MJ Neuropsychobiology; 2004; 50(1):89-101. PubMed ID: 15179026 [TBL] [Abstract][Full Text] [Related]
46. Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review. White E; Kennedy T; Ruffell S; Perkins D; Sarris J Int J Toxicol; 2024; 43(3):327-339. PubMed ID: 38363085 [TBL] [Abstract][Full Text] [Related]
47. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Dos Santos RG; Osório FL; Crippa JA; Hallak JE Braz J Psychiatry; 2016 Mar; 38(1):65-72. PubMed ID: 27111702 [TBL] [Abstract][Full Text] [Related]
48. Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Soler J; Elices M; Franquesa A; Barker S; Friedlander P; Feilding A; Pascual JC; Riba J Psychopharmacology (Berl); 2016 Mar; 233(5):823-9. PubMed ID: 26612618 [TBL] [Abstract][Full Text] [Related]
50. Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. Cameron LP; Benson CJ; Dunlap LE; Olson DE ACS Chem Neurosci; 2018 Jul; 9(7):1582-1590. PubMed ID: 29664276 [TBL] [Abstract][Full Text] [Related]
51. A rapid analytical strategy for the determination of ayahuasca alkaloids in non-ritualistic approaches by UHPLC-MS/MS. Eller S; Borges GR; Ossanes DS; Birk L; Scheid C; Yonamine M; Grossi P; Merib JO; Oliveira TF Forensic Sci Int; 2020 Jul; 312():110298. PubMed ID: 32387868 [TBL] [Abstract][Full Text] [Related]
52. Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay. Kummrow F; Maselli BS; Lanaro R; Costa JL; Umbuzeiro GA; Linardi A Environ Mol Mutagen; 2019 Apr; 60(3):269-276. PubMed ID: 30488498 [TBL] [Abstract][Full Text] [Related]
53. Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment. Brierley DI; Davidson C Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):263-72. PubMed ID: 22691716 [TBL] [Abstract][Full Text] [Related]
54. Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience. Dos Santos RG; Hallak JEC Epilepsy Behav; 2021 Aug; 121(Pt B):106300. PubMed ID: 31182391 [TBL] [Abstract][Full Text] [Related]
55. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312 [TBL] [Abstract][Full Text] [Related]
56. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Uthaug MV; Mason NL; Toennes SW; Reckweg JT; de Sousa Fernandes Perna EB; Kuypers KPC; van Oorsouw K; Riba J; Ramaekers JG Psychopharmacology (Berl); 2021 Jul; 238(7):1899-1910. PubMed ID: 33694031 [TBL] [Abstract][Full Text] [Related]
57. The globalization of ayahuasca: harm reduction or benefit maximization? Tupper KW Int J Drug Policy; 2008 Aug; 19(4):297-303. PubMed ID: 18638702 [TBL] [Abstract][Full Text] [Related]
58. Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage. Pires AP; De Oliveira CD; Moura S; Dörr FA; Silva WA; Yonamine M Phytochem Anal; 2009; 20(2):149-53. PubMed ID: 19140116 [TBL] [Abstract][Full Text] [Related]
59. [The potential use of ayahuasca in psychiatry]. Frecska E; Bokor P; Andrassy G; Kovacs A Neuropsychopharmacol Hung; 2016 Jun; 18(2):79-86. PubMed ID: 27390204 [TBL] [Abstract][Full Text] [Related]